(NASDAQ: ONC) Beigene's forecast annual revenue growth rate of 20.08% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 62.21%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.75%.
Beigene's revenue in 2025 is $4,175,868,000.On average, 4 Wall Street analysts forecast ONC's revenue for 2025 to be $7,183,180,378,418, with the lowest ONC revenue forecast at $7,090,650,255,341, and the highest ONC revenue forecast at $7,234,882,568,760. On average, 4 Wall Street analysts forecast ONC's revenue for 2026 to be $8,613,877,080,262, with the lowest ONC revenue forecast at $7,904,290,023,004, and the highest ONC revenue forecast at $8,890,396,723,136.
In 2027, ONC is forecast to generate $10,166,809,194,251 in revenue, with the lowest revenue forecast at $8,665,586,287,159 and the highest revenue forecast at $11,133,028,169,672.